Verastem (VSTM) Current Deferred Revenue (2011 - 2023)

Verastem (VSTM) recorded quarterly Current Deferred Revenue of $327000.0 in Q4 2023, up 68.56% quarter-over-quarter from $194000.0 in Q1 2018.

Verastem (VSTM) Current Deferred Revenue (2011 - 2023) Analysis & Trends

Verastem's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $327000.0 for Q4 2023.

  • In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $327000.0; the TTM figure through Dec 2023 stood at $327000.0 (changed N/A YoY), while the FY2023 annual figure was $327000.0, changed N/A from the prior year.
  • Current Deferred Revenue was $327000.0 for Q4 2023 at Verastem, up from $194000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $327000.0 in Q4 2023 to a low of $327000.0 in Q4 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Verastem 407.42 Mn 225.74 Mn 15.90 Mn

Historic Data

Download Data
DateValue
Dec 31, 2023 327,000.00
Mar 31, 2018 194,000.00
Dec 31, 2017 190,000.00
Sep 30, 2017 186,000.00
Jun 30, 2017 81,000.00
Mar 31, 2017 179,000.00
Dec 31, 2016 527,000.00
Sep 30, 2016 171,000.00
Jun 30, 2016 167,000.00
Mar 31, 2016 164,000.00
Dec 31, 2015 160,000.00
Sep 30, 2015 156,000.00
Jun 30, 2015 152,000.00
Mar 31, 2015 148,000.00
Dec 31, 2014 144,000.00
Sep 30, 2014 137,000.00
Jun 30, 2014 72,000.00
Mar 31, 2014 28,000.00
Dec 31, 2013 38,000.00
Sep 30, 2013 43,000.00